ReviewArchives of endocrinology and metabolism2022
Normocalcemic primary hyperparathyroidism.
Review in Archives of endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 56 citations in OpenAlex.
- Editorial for the Special Issue Entitled "Novel Aspects of Endocrine Care: From Patient-Centered Management of Endocrine Diseases to Guidelines Standards".Journal of clinical medicine · 2026Article
- Challenges and unmet needs of [European journal of nuclear medicine and molecular imaging · 2026Article
- A comparative analysis of osteoporosis, nephrolithiasis, and metabolic/cardiovascular comorbidities in normocalcemic and mild primary hyperparathyroidism.Journal of bone and mineral metabolism · 2026Article
- Characteristics of Patients with Primary Hyperparathyroidism with Localization Failure of the Causative Parathyroid Gland: A Clinical Report and Literature Review.Internal medicine (Tokyo, Japan) · 2026Review
- Future Directions in Hypercalcemic and Normocalcemic Primary Hyperparathyroidism: FRAXplus for 10-Year Fracture Risk Assessment (A Retrospective Study).Life (Basel, Switzerland) · 2026Article
- Prevalence and determinants of secondary hyperparathyroidism: IMOS-2021.Scientific reports · 2026Article
- Heterogeneous Phenotypes of Primary Hyperparathyroidism in Romania: Characterization of a Large Cohort.Journal of clinical medicine · 2026Article
- Effects of Normocalcemic Hyperparathyroidism on Structural Bone Compromise: A Prospective Observational Cohort Study.Journal of bone metabolism · 2026Article
- Utility of albumin-adjusted calcium and calcium‒phosphorus difference in screening for primary hyperparathyroidism.BMC endocrine disorders · 2026Article
- Serum Biomarker-Based Diagnostic Tools for Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis with Implications for Primary Care.Healthcare (Basel, Switzerland) · 2026Review
- Renal calcifications and primary hyperpara-thyroidism in a tertiary care hospital center of North Africa: a single-center experience.Medicine and pharmacy reports · 2026Article
- Association Between Biochemical Parameters, Parathyroid Gland Morphometry, and Dual-Phase MIBI SPECT/CT Findings in Primary Hyperparathyroidism.Journal of clinical medicine · 2026Article
- Three Malagasy Cases of Severe Bone Complications Revealing Primary Hyperparathyroidism.Case reports in endocrinology · 2026Article
- Article
- Serum PTH ≥ 40 pg/mL as a Marker of Bone Fragility and Vitamin D Deficiency in Periodontitis Patients: Biochemical, Densitometric and Genetic Evidence.Biomolecules · 2025Article
- Paget's Disease of Bone and Normocalcemic Variant of Primary Hyperparathyroidism in an Osteoporotic Male: Exceptional Coexistence.Reports (MDPI) · 2025Article
- Patients with normocalcemic versus hypercalcemic hyperparathyroidism: What's really the difference?American journal of surgery · 2025Article
- Unraveling the Paradox of Vitamin D Status in Primary Hyperparathyroidism: An Incidental Finding or an Unexpected Consequence?International journal of molecular sciences · 2025Article
- An Analysis of Primary Hyperparathyroidism in Individuals Diagnosed with Multiple Endocrine Neoplasia Type 2.Diseases (Basel, Switzerland) · 2025Review
- Hypoparathyroidism in adults with iron overload diseases (IOD): evidence of a subclinical phenotype.Endocrine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Normocalcemic primary hyperparathyroidism (PHPT) is a newer phenotype of PHPT defined by elevated PTH concentrations in the setting of normal serum calcium levels. It is increasingly being diagnosed in the setting of evaluation for nephrolithiasis or metabolic bone diseases. It is important to demonstrate that PTH values remain consistently elevated and to measure ionized calcium levels to make the diagnosis. A diagnosis of normocalcemic disease is one of exclusion of secondary forms of hyperparathyroidism, including vitamin D deficiency, renal failure, medications, malabsorption, and hypercalciuria. Lack of rigorous diagnostic criteria and selection bias of the studied populations may explain the different rates of bone and renal complications. The natural history still remains unknown. Caution should be used in recommending surgery, unless clearly indicated. Here we will review the diagnostic features, epidemiology, clinical presentation, natural history, medical and surgical management of normocalcemic PHPT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.